MET and non-small cell lung carcinoma: Although no targeted therapy is approved specifically for metastatic NSCLC with high-level MET amplification, MET tyrosine kinase inhibitors (TKIs) have demonstrated promising efficacy3,10,18 and are recommended in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).19